Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8911230 | 0.90 | GABRA1 (0.35) | GABRA1GABRB2CASP1MAPTGAA | |
| SCHEMBL8911234 | 0.90 | GABRA1 (0.35) | GABRA1GABRB2CASP1MAPTGAA | |
| SCHEMBL5548473 | 0.88 | GABRA1 (0.42) | GABRA1GABRB2MAPTGAATSHR | |
| SCHEMBL31290769 | 0.86 | GABRA1 (0.41) | GABRA1GABRB2CASP1MAPTIMPDH2 | |
| SCHEMBL454406 | 0.86 | GABRA1 (0.41) | GABRA1GABRB2CASP1MAPTIMPDH2 | |
| Ethylene SCHEMBL27977906 | 0.86 | GABRA1 (0.41) | GABRA1GABRB2MAPTGAATSHR | |
| Hydrochloric Acid SCHEMBL6307100 | 0.84 | GABRA1 (0.39) | GABRA1GABRB2CASP1MAPTGAA | |
| SCHEMBL1334151 | 0.82 | GABRA1 (0.41) | GABRA1GABRB2MAPTGAATSHR | |
| SCHEMBL7936360 | 0.81 | CYP3A4 (0.46) | GABRA1GABRB2CASP1MAPTGAA | |
| SCHEMBL6004557 | 0.81 | GABRA1 (0.50) | GABRA1GABRB2CASP1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4604484-A | WITH PROPYLENE IN PRESENCE OF ALUMINUM ANILIDE | ETHYL CORPORATION (US) | 1986-08-05 | — | — | US | claimed |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2011-05-12 | — | — | US | disclosed |
| US-7696246-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100069379-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-03-18 | — | — | US | disclosed |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | LIGAND PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0099079-B1 | CO-VULCANIZABLE COMPOSITIONS BASED ON FLUOROELASTOMERS AND POLYMERIC COMPOUNDS WITH A PERFLUOROETHERIC STRUCTURE | AUSIMONT S.p.A. (IT) | 1987-05-13 | — | — | EP | disclosed |
| US-4611045-A | POLYURETHANES MODIFIED WITH CHAIN EXTENDERS | ETHYL CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4611045-A | POLYURETHANES MODIFIED WITH CHAIN EXTENDERS | ETHYL CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4604484-A | WITH PROPYLENE IN PRESENCE OF ALUMINUM ANILIDE | ETHYL CORPORATION (US) | 1986-08-05 | — | — | US | disclosed |
| US-4604484-A | WITH PROPYLENE IN PRESENCE OF ALUMINUM ANILIDE | ETHYL CORPORATION (US) | 1986-08-05 | — | — | US | disclosed |
| US-4530969-A | Vulcanized with peroxides | MONTEDISON S.P.A. (IT) | 1985-07-23 | — | — | US | disclosed |
| US-4440952-A | POLYURETHANE CHAIN EXTENDER | ETHYL CORPORATION (US) | 1984-04-03 | — | — | US | disclosed |
| US-4440952-A | POLYURETHANE CHAIN EXTENDER | ETHYL CORPORATION (US) | 1984-04-03 | — | — | US | disclosed |
| EP-0099079-A1 | Co-vulcanizable compositions based on fluoroelastomers and polymeric compounds with a perfluoroetheric structure | AUSIMONT S.p.A. (IT) | 1984-01-25 | — | — | EP | disclosed |
| US-4324553-A | OXIDATION COLOR DYES | L'OREAL (FR) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069379-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | GABRA1 280/4885GABRB2 416/4885CASP1 4498/4885 |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | GABRA1 280/4885GABRB2 416/4885CASP1 4498/4885 |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | FSHR, CYP19A1, ESR2 | GABRA1 768/4885GABRB2 840/4885CASP1 4681/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | GABRA1 280/4885GABRB2 416/4885CASP1 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.